In this April 9, 2020 file photo, a chemist displays hydroxychloroquine tablets in New Delhi, India. U.S. regulators are revoking emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19. The Food and Drug Administration said Monday, June 15 that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. (AP Photo/Manish Swarup, File)
By Matthew Perrone
The U.S. Food and Drug Administration is revoking its emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause deadly side effects.
The agency said Monday that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs pose a greater risk to patients than any potential benefits.
The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure, and muscle or nerve damage.
The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities. The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.
On Thursday, a National Institutes of Health expert panel revised its guidelines to specifically recommend against the drug’s use except in formal studies.
Trump aggressively pushed the drug beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he took the drug preemptively against infection.
Founder, Chairman and Principal Analyst of Constellation Research Inc., Ray Wang, reveals how Tesla's Robotaxi is going to disrupt the transportation industry.
Have Taylor Swift fans dubbed Flava Flav as King of the Swifties? Plus, his new partnership with Old Spice and if he will ever go back to the Olympics. Watch!
Education Reporter for The Wall Street Journal, Doug Belkin, discusses his latest piece and delves into why incoming freshmen are preferring southern schools.
Founder & CEO of FLYR, Alex Mans, joins Cheddar to talk about the current state of the airline industry and how his company is updating technology in the sky.
Spirit Halloween CEO, Steve Silverstein, stops by Cheddar to talk SNL, this year's top costume ideas and why you should watch out for Spirit Christmas. Watch!
